cerrar
Tagged with Novartis

Karin Blumer – Director Global Patient Engagement, Novartis…
Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape…

Roche to Disentangle from Novartis, Ending Two Decades of…
After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7…

Angeline Ho – Communication & Patient Advocacy Lead,…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in…

Denmark’s Patient Data Goldmine: 5 Country Managers Have Their…
Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of…

10 Turkish Pharma Execs Talk Investment Strategies
In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational…

Peter Drøidal – Country Manager Denmark & Nordic Head…
Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the…

5 Management Tips from APAC Life Science Leaders
The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures,…

China Pharma News: Fosun Sales up 20%; MNC Price Manoeuvres Lead…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis,…

Turkey: A Pharma Talent Hotbed
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of…

How Pricing is Straining Turkish Pharma’s Sustainability
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over…

Novartis Mexico Gets “Aggressive”; Country President Foresees…
During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando…

Saudi’s Centralised Procurement Body: Pharma Leaders Have…
As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here